Publications by authors named "Stefano Cereda"

Claim this Profile
I
Immunotherapy in small bowel adenocarcinoma: a potential role?
Francesco Vitiello, Stefano Cereda, Silvia Foti, Nicole Liscia, Elena Mazza

Immunol Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.
Caterina Peraldo-Neia, Giuliana Cavalloni, Elisabetta Fenocchio, Celeste Cagnazzo, Loretta Gammaitoni, Stefano Cereda

PLoS One· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: a preliminary study.
Massimo Venturini, Claudio Sallemi, Giulia Agostini, Paolo Marra, Stefano Cereda

Br J Radiol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial.
Michele Reni, Erica Dugnani, Stefano Cereda, Carmen Belli, Gianpaolo Balzano

Clin Cancer Res· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Francesco Leone, Donatella Marino, Stefano Cereda, Roberto Filippi, Carmen Belli

Cancer· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data.
Lorenzo Fornaro, Caterina Vivaldi, Stefano Cereda, Francesco Leone, Giuseppe Aprile

J Exp Clin Cancer Res· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In reply to Ren et al.
Paolo Passoni, Michele Reni, Giovanni M Cattaneo, Najla Slim, Stefano Cereda

Int J Radiat Oncol Biol Phys· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study.
Paolo Passoni, Michele Reni, Giovanni M Cattaneo, Najla Slim, Stefano Cereda

Int J Radiat Oncol Biol Phys· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line therapy in advanced biliary tract cancer: what should be the standard?
Stefano Cereda, Carmen Belli, Alessia Rognone, Elena Mazza, Michele Reni

Crit Rev Oncol Hematol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial.
Michele Reni, Stefano Cereda, Michele Milella, Anna Novarino, Alessandro Passardi

Eur J Cancer· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant therapy in resectable pancreatic cancer: a critical review.
Carmen Belli, Stefano Cereda, Santosh Anand, Michele Reni

Cancer Treat Rev· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back.
Amir Avan, Paola Pacetti, Michele Reni, Michele Milella, Enrico Vasile, Stefano Cereda

Int J Cancer· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced pancreatic adenocarcinoma.
Giovanni M Cattaneo, Paolo Passoni, Barbara Longobardi, Najla Slim, Michele Reni, Stefano Cereda

Radiother Oncol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preoperative chemotherapy does not adversely affect pancreatic structure and short-term outcome after pancreatectomy.
Nicolò Pecorelli, Marco Braga, Claudio Doglioni, Gianpaolo Balzano, Michele Reni, Stefano Cereda

J Gastrointest Surg· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma.
Giuseppe Aprile, Claudio Avellini, Michele Reni, Micol Mazzer, Luisa Foltran, Stefano Cereda

Tumour Biol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer.
Paolo Giorgio Arcidiacono, Silvia Carrara, Michele Reni, Maria Chiara Petrone, Stefano Cappio, Stefano Cereda

Gastrointest Endosc· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of taxanes in pancreatic cancer.
Carmen Belli, Stefano Cereda, Michele Reni

World J Gastroenterol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Michele Reni, Gianpaolo Balzano, Giuseppe Aprile, Stefano Cereda, Paolo Passoni

Ann Surg Oncol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant treatment in biliary tract cancer: to treat or not to treat?
Stefano Cereda, Carmen Belli, Michele Reni

World J Gastroenterol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Michele Reni, Stefano Cereda, Alessia Rognone, Carmen Belli, Michele Ghidini

Cancer Chemother Pharmacol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy.
Elisa Giovannetti, Paola Pacetti, Michele Reni, Leticia G Leon, Andrea Mambrini, Stefano Cereda

Pharmacogenomics· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial.
Stefano Cereda, Michele Reni, Alessia Rognone, Clara Fugazza, Michele Ghidini

Chemotherapy· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment trends in metastatic pancreatic cancer patients: Is it time to change?
Michele Reni, Lara Maria Pasetto, Alessandro Passardi, Michele Milella, Andrea Mambrini, Stefano Cereda

Dig Liver Dis· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.
Stefano Cereda, Michele Reni, Alessia Rognone, Michele Ghidini, Carmen Belli

Anticancer Res· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.
Stefano Cereda, Paolo Passoni, Michele Reni, Maria G Viganò, Luca Aldrighetti

Cancer· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis